Day: January 7, 2025

SAN FRANCISCO, Jan. 07, 2025 (GLOBE NEWSWIRE) — Serve Robotics Inc. (“Serve” or the “Company”) (Nasdaq: SERV), a leading autonomous sidewalk delivery company, announced today that the Company has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,210,525 shares of common stock, pursuant to a registered direct offering, expected to result in gross proceeds of approximately $80.0 million, before deducting placement agent fees and other offering expenses. The offering is expected to close on or about January 7, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use net proceeds from the offering for general corporate purposes, including working capital. Northland Capital Markets is acting as the exclusive placement...

Continued network enhancements prepare network for evolving customer needs BASKING RIDGE, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) — When customers choose Verizon—they’re not just choosing a network, but a future-ready partner. In anticipation of the evolving landscape of mobile consumption, where video calls are replacing traditional voice calls, streaming dominates entertainment, gaming has moved to the cloud, and factories are running their operations on 5G private networks, Verizon engineers are pushing the boundaries of mobile technology. Using carrier aggregation and Verizon’s 5G virtualized technology, engineers recently achieved 5.5 Gbps download speeds. That’s the equivalent of downloading 266 Taylor Swift albums a minute or streaming 3,056 Hulu episodes per hour. “Customers expect the gold standard from Verizon and...

Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the “Meeting”), as set out in the Company’s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, as auditor...

MINNEAPOLIS, MN, Jan. 07, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold a special meeting of its shareholders at 10.30am EST on Friday, January 17, 2025. The Board of Directors of the Company has authorized a virtual meeting of its shareholders to be held on Friday, January 17, 2025, at 10:30 a.m. Eastern Standard Time to seek approval for several proposals. The record date was January 3, meaning that all shareholders of record on January 3, 2025, will be entitled to vote on the proposals. The Company has several proposals it requires approval from its shareholders for, the main one being as a as a result of certain acquisition transactions entered into. Shareholder Proposals:To approve, for purposes of complying with NYSE American Rule 713, pursuant to the terms of...

First one of the WISeSat new generation satellites to be launched on January 14 Geneva, Switzerland, Jan. 07, 2025 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company specializing in Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that in cooperation with WISeSat AG (“WISeSat”), both subsidiaries of WISeKey International Holding Ltd (NASDAQ: WKEY; SIX: WIHN), will launch six next-generation satellites in 2025. Each satellite will feature incremental advancements in post-quantum cryptography and secure communication technologies, further solidifying their leadership in satellite-based IoT solutions. The first of the new generation satellites will be launched on January 14, 2025, from the Vandenberg Space Force Base in California,...

KUALA LUMPUR, Malaysia, Jan. 07, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global,” or the “Company”), today announced the carve-out of its wholly owned subsidiary, V Capital Consulting Group Limited (“VCCG”), for listing on the Nasdaq Capital Market. VCIG will retain majority control of VCCG. This strategic initiative aims to enable both companies to focus on their core competencies, better serve their respective markets, and enhance growth potential and value creation for shareholders. The carve-out has been executed pursuant to the Stock Sale and Business Separation Agreement entered into on December 30, 2024, through the sale of VCI Global’s subsidiaries V Capital Consulting Limited and V Capital Advisory Sdn. Bhd. to VCCG. This strategic move is designed to unlock value for shareholders by allowing both...

Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) — Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial leadership roles. Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered environments while managing investor...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET. A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days following the event. About Anaptys Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is...

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC-4539, a potential best-in-class LSD1 inhibitor, is the first designed to be reversible and CNS penetrant for small-cell lung cancerSalt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared a clinical trial application (CTA) for a Phase 1 clinical trial of REC-3565, a potential best-in-class MALT1 inhibitor for B-cell malignancies. For REC-3565, the total addressable population could include a range of hematological indications,...